Mesoridazine

CHEMBL1088 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

386.6 g/mol

LogP

4.5

Phase

4

A phenothiazine antipsychotic medication used to treat schizophrenia in patients who have not responded to other treatments. Due to its risk of serious heart rhythm abnormalities, its use is now very limited.

الوزن الجزيئي

386,6000 g/mol

LogP

4,50

TPSA

68,10 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Schizophrenia Bipolar Disorder Obesity

آلية العمل

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21

InChI

InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

Molecular Formula

C21H26N2OS2

HBD / HBA

- / 5

الروابط القابلة للدوران

4

الذرات الثقيلة

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A phenothiazine antipsychotic medication used to treat schizophrenia in patients who have not responded to other treatments. Due to its risk of serious heart rhythm abnormalities, its use is now very limited.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Mesoridazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1088. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4078. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Mesoridazine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C21H26N2OS2

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.